^
Association details:
| Biomarker: | PD-L1 underexpression + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
370P - Outcomes in patients with EGFR-mutant locally advanced or metastatic NSCLC co-mutations receiving aumolertinib as first-line treatment: A retrospective study
Published date:
11/28/2022
Excerpt:
We retrospectively collected data from 52 EGFR-mutant NSCLC patients with co-mutations...In the subgroup analysis of genotypes, ORR and DCR was 71.4 % and 100 % in TP53 mutation, 72.4 % and 100 % in cell cycle signaling pathway related genes, 66.7 % and 100 % in PIK3CA co-mutation, 83.3 % and 97.7 % in PD-L1 TPS 0-1, 55.6 % and 100 % in PD-L1 TPS ≥ 1...
